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Analysis of Florida and New York state hospital
discharges suggests that carotid stenting in
symptomatic women is associated with significant
increase in mortality and perioperative morbidity
compared with carotid endarterectomy
Ageliki G. Vouyouka, MD,a Natalia N. Egorova, PhD, MPH,b Eugene A. Sosunov, PhD,c
Alan J. Moskowitz, MD,b Annetine Gelijns, PhD,b Michael Marin, MD,a and Peter L. Faries, MD,a New York, NY
Background: Although large randomized studies have established the efficacy and safety of carotid endarterectomy (CEA)
and, recently, carotid artery stenting (CAS), the under-representation of women in these trials leaves the comparison of
risks to benefits of performing these procedures on women an open question. To address this issue, we reviewed the
hospital outcomes and delineated patient characteristics predicting outcome in women undergoing carotid interventions
using New York and Florida statewide hospital discharge databases.
Methods: We analyzed in-hospital mortality, postoperative stroke, cardiac postoperative complications, and combined
postoperative stoke and mortality in 20,613 CEA or CAS hospitalizations for the years 2007 to 2009. Univariate and
multiple logistic regression analyses of variables were performed.
Results:CEAwas performed in 16,576 asymptomatic and1744 symptomaticwomen andCAS in 1943 asymptomatic and350
symptomatic women. Compared with CAS, CEA rates, in asymptomatic vs symptomatic, were significantly lower for
in-hospitalmortality (0.3% vs 0.8% and0.4% vs 3.4%), stroke (1.5% vs 2.6% and3.5% vs 9.4%), and combined stroke/mortality
(1.7% vs 3.1% and 3.8% vs 10.9%). In cohortsmatched by propensity scores, the same trend favoringCEA remained significant
in symptomatic women. There was no difference in cardiac complication rates among asymptomatic women, but among
symptomatic woman cardiac complications were more frequent after CAS (10.6% vs 6.5%; P .0077). Among symptomatic
women, the presence of renal disease, coronary artery disease, or age>80 years increased the risk of CAS over CEA threefold
for the composite end point of stroke or death. For asymptomatic women only in those with coronary artery disease or
diabetes, there was a statistical difference in the composite mortality/stroke rates favoring CEA (1.9% vs 3.3% and 1.7% vs
3.4%, respectively). After adjusting for relevant clinical and demographic risk factors and hospital annual volume, for CAS vs
CEA, the risk of the composite end point of stroke or mortality was 1.7-fold higher in symptomatic and 3.4-fold higher in
asymptomatic patients.Medicaid insurance, symptomatic patient, history of cancer, and presence of heart failure on admission
were among other strong predictors of composite stroke/mortality outcome.
Conclusions: Databases reflecting real-world practice performance and management of carotid disease in women suggest
that CEA compared with CAS has overall better perioperative outcomes in women. Importantly, CAS is associated with
significantly higher morbidity in certain clinical settings and this should be taken into account when choosing a
revascularization procedure. (J Vasc Surg 2012;56:334-42.)
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vBecause of the high prevalence of carotid artery disease
in the elderly population, carotid interventions, including
carotid endarterectomy (CEA) and carotid artery stenting
(CAS), are among the most common procedures per-
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334ormed by vascular surgeons and interventionalists. In the
ate 1980s and 1990s, large trials validated the safety and
uperiority of CEA over medical treatment in preventing
omplications from carotid atherosclerotic disease.1-5
owever, the benefit of CEA in women, especially those
ith asymptomatic disease, is not well established. Further-
ore, during the last decade, CAS has emerged as an
lternative carotid intervention for certain patients with
ritical carotid stenosis for whom CEA is associated with
igh risk. Several trials6-8 have compared the outcomes
rom CAS and CEA, with inconsistent conclusions, partic-
larly with regard to sex. These trials were not designed for
ex subgroup analysis and, therefore, were not powered to
nswer questions about the efficacy of carotid intervention
n women, especially those with asymptomatic disease.
The recent Carotid Revascularization Endarterectomy
s. Stent Trial (CREST) trial did not show amodification of
he treatment effect by sex (P  .34).9 However, women
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Volume 56, Number 2 Vouyouka et al 335undergoing CAS had significantly higher perioperative
stroke rates than those undergoing CEA (5.5% vs 1.7%; P
.01). Interestingly, equivalent rates of perioperative myo-
cardial infarction (MI) were observed among women un-
dergoing CAS and CEA (1.5% vs 1.7%, respectively; P 
.81).
Thus, the optimal use of CEA and CAS in the treat-
ment of carotid disease in women remains an open ques-
tion. We analyzed the state data of 20,613 hospitalizations
of women in New York and Florida who underwent a
carotid intervention. We compared immediate periopera-
tive outcomes, identified high-risk clinical groups, and
delineated patient characteristics predicting outcomes in
women with atherosclerotic carotid artery stenosis under-
going revascularization with CEA or CAS.
METHODS
Data sources. The hospital discharge data sets from
the New York State Health Department, Statewide Plan-
ning and Research Cooperative System, and the Florida
Department of Health for years 2007 to 2009 were used in
this study. These databases contain patient age, race, sex,
diagnoses, procedures, and charges for every hospital dis-
charge. They also provide an indicator that shows whether
a diagnosis was present on admission (POA) and allows
complications to be distinguished from pre-existing condi-
tions. The POA flag has been a key in measuring the
provided health care quality and in receiving appropriate
reimbursement for services rendered.10
Patient population. The analysis was restricted to
women who underwent CAS or CEA during their hospi-
talization. Carotid intervention hospitalizations were iden-
tified by the International Classification of Diseases, 9th
Clinical Modification (ICD-9-CM) procedure code 00.63
for CAS and 38.12 for CEA in the primary or any secondary
position. We excluded hospitalizations with endovascular
repair of endocranial vessels and carotid dissection (primary
diagnoses) as well as concomitant coronary artery bypass
grafting and mitral or aortic valve replacement.
The process of adoption of the symptomatic codes
(Appendix I, online only) has been described elsewhere.11
Briefly, symptomatic presentation was defined if admitting
or primary diagnosis codes 433.11 (occlusion and stenosis
of carotid artery with cerebral infarction), 433.31 (occlu-
sion and stenosis of multiple and bilateral arteries with
cerebral infarction), 434.11 (cerebral embolism with cere-
bral infarction), 434.91 (unspecified cerebral artery occlu-
sion with cerebral infarction), 435.8 and 435.9 (transient
ischemic attack), 443.21 (dissection of carotid artery as
secondary diagnosis), 434.01 (thrombosis of cerebral arter-
ies with cerebral infarction), 362.3 (retinal vascular occlu-
sion), and 362.84 (retinal ischemia) were present on admis-
sion. Asymptomatic patients were defined as those without
these diagnosis codes present at the time of admission for
their carotid procedure. A modified Elixhauser’s coding
algorithm was used to define baseline comorbidities.12
The POA diagnoses included as comorbidities (primary
and any secondary diagnoses) were cardiac, pulmonary, 1ulmonary circulation, peripheral vascular disease (PVD),
enal disease, hypertension, lipid metabolism disorder, di-
betes, obesity, neck cancer, and other cancer (Appendix
I, online only). Mortality, postoperative stroke, postoper-
tive cardiac complications (Appendix II, online only), and
ombined postoperative stroke or mortality (stroke/mor-
ality) were evaluated as our primary outcomes in total,
symptomatic, and symptomatic cohorts. Clinically high-
isk groups were identified as octogenarians, women of
lack race, and women with renal disease, diabetes, or
oronary artery disease. We used the same definitions of
ostoperative stroke as previously described.11
Statistical analysis. Patients’ baseline characteristics
nd observed rates of complications were compared with
he 2 test for categoric variables and the t-test for contin-
ous variables. To account for pre-existing conditions,
ultivariable regression analysis was performed. Multivari-
ble logistic regression models were developed for each
atient stratum (asymptomatic, symptomatic, and total).
he dependent variable was the outcome (postoperative
troke, death, or stroke and death) and the independent
ariables were patient demographics (age and race), base-
ine clinical characteristics (congestive heart failure, cardiac
rrhythmia, valvular and coronary disease, chronic obstruc-
ive pulmonary disease, pulmonary circulation, renal fail-
re, diabetes, hypertension, hyperlipidemia, liver disease,
eripheral vascular disease, cancer, rheumatoid arthritis,
besity), hospitalization type, insurance status, year of pro-
edure, and annual hospital volume in CAS or CEA. All
ariables found on univariate analysis having P  .2 were
ntered into the multivariable model. Only variables with
 .05 were left in the final model. The fit of the model to
he data was assessed using the concordance index (C
tatistic) and the Hosmer-Lemeshow test. To decrease the
otential observational bias, the outcomes after CAS and
EAwere also compared in cohorts of the womenmatched
y propensity scores.
Propensity scores were calculated with logistic regres-
ion model where the dependent variable was type of
rocedure and independent variables included patient de-
ographics and clinical characteristics, year of procedure,
nsurance status, type of hospitalization, and hospital an-
ual volume. CAS and CEA hospitalizations were matched
:1 using the greedy match algorithm.13 Differences be-
ween matched pairs were evaluated using the paired t-test
or continuous variables and the McNemar test for binary
ata (Appendix III, online only). Statistical analysis was
erformed with SAS software (SAS Institute Inc, Cary,
C). P  .05 was considered statistically significant.
ESULTS
Patient population. There were 20,620 carotid inter-
ention hospitalizations for women in New York and Flor-
da states during 2007 to 2009. CAS was more likely to be
erformed in New York than in Florida (13.8 vs 9.6% of all
arotid procedures; P .0001). CAS rates increased during
he study period in both states: from 13.1% in 2007 to
4.3% in 2009 in New York (P  .05) and from 8.6% in
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lent outcomes (data not shown).
CEAwas performed in 16,576 asymptomatic and 1744
symptomatic women and CAS was performed in 1948
asymptomatic and 352 symptomatic women. Seven women
(five asymptomatic and two symptomatic) received CAS
and CEA at the same hospitalization. One had stroke and
none died. Because the sequence of the procedures was not
identifiable, these hospitalizations were excluded from the
final analysis.
Demographics and comorbidities for patients who un-
Table I. Baseline characteristics of women who underwen
Variablea
CEA CAS
(n  18,320) (n  229
Age, years 72.0  0.07 70.1  0
Octogenarians 23.48 20.76
Race
Native Americans 0.27 0.48
Asians 0.52 0.48
Blacks 4.66 5.76
Whites 90.33 86.39
Other race 3.01 5.63
Unknown race 1.20 1.26
Emergency hospitalization 21.35 33.14
Comorbid conditions
Symptomatic presentation 9.52 15.26
Cardiac 45.28 52.73
Congestive heart failure 6.10 10.51
Cardiac arrhythmia 10.27 12.08
Valvular disease 7.90 7.20
Coronary disease 36.18 44.27
Pulmonary 22.71 20.06
COPD 2.06 1.88
Other pulmonary diseases 20.88 18.58
Pulmonary circulation 1.43 1.31
Hypertension 80.67 76.80
Hyperlipidemia 58.19 57.17
Diabetes 30.17 31.09
Liver disease 0.59 0.65
Peripheral vascular disease 18.36 22.55
Significant LE ischemia 0.39 0.65
Renal atherosclerosis 1.27 2.53
Other vascular atherosclerosis 17.36 20.98
Renal disease 6.39 8.59
Cancer 0.88 1.61
Neck cancer 0.46 1.79
Other cancer 0.83 1.00
Rheumatoid arthritis 2.93 2.57
Obesity 7.01 6.28
Procedure type
CAS 0.00 100.00
CEA 100.00 0.00
Insurance status
Medicare 76.61 71.09
Medicaid 2.54 5.28
Commercial 18.36 19.93
Other insurance 1.21 1.92
Uninsured 1.28 1.79
Annual hospital volume
CAS 14  0.16 45.88  0
CEA 109.5  0.58 107.6  1
CAS, Carotid artery stenting; CEA, carotid endarterectomy; COPD, chroni
aContinuous data are presented as the mean  standard error and categoricderwent a carotid procedure are presented in Table I. domen undergoing CEA were older (72.0 vs 70.1 years;
 .0001), had a higher proportion of octogenarians
23.5% vs 20.8%; P .0036), and more pulmonary comor-
idities (22.7% vs 20.1%; P  .005) and hypertension
80.7% vs 76.8%; P  .0001) compared with the endovas-
ular cohort. The CAS group had higher frequency of
ymptomatic patients and higher rates of cardiac, PVD,
eck cancer, and renal failure (Table I). Only 11.2% of all
rocedure-associated hospitalizations were for symptom-
tic disease (9.5% of all CEAs and 15.3% of all CAS; P 
0001). The symptomatic and asymptomatic cohorts were
otid intervention in Florida and New York in 2007-2009
P
Asymptomatic Symptomatic
P(n  18,519) (n  2094)
.0001 71.83  0.07 71.23  0.24 .0152
.0036 22.84 26.03 .0011
.0857 0.29 0.38 .444
.7808 0.51 0.62 .4943
.0205 4.45 7.69 .0001
.0001 90.26 86.63 .0001
.0001 3.27 3.58 .4528
.7741 1.21 1.10 .6428
.0001 17.24 70.68 .0001
.0001 0.00 100.00 .99
.0001 45.79 47.28 .2567
.0001 6.36 8.60 .0001
.0075 10.14 13.42 .0001
.2339 7.71 8.88 .0573
.0001 37.26 35.43 .1003
.0054 22.28 23.64 .1575
.5596 2.07 1.77 .3551
.0103 20.45 22.16 .0669
.6417 1.27 2.72 .0001
.0001 79.89 83.33 .0002
.3537 57.74 61.03 .0038
.366 30.03 32.47 .021
.7297 0.61 0.53 .634
.0001 19.00 17.29 .0571
.069 0.41 0.53 .442
.0001 1.44 1.10 .206
.0001 17.93 16.24 .0542
.0001 6.33 9.11 .0001
.0007 0.83 2.01 .0001
.0001 0.59 0.81 .2141
.3937 0.72 2.01 .0001
.3416 2.82 3.44 .1115
.1951 6.65 9.41 .0001
.99 10.49 16.71 .0001
.99 89.52 83.29 .0001
.0001 76.63 70.39 .0001
.0001 2.68 4.25 .0001
.0676 18.28 20.77 .0053
.0047 1.29 1.34 .8416
.0472 1.12 3.25 .0001
.0001 17.30  0.19 19.76  0.62 .0002
.2637 110.40  0.56 99.73  1.60 .0001
ructive pulmonary disease; LE, lower extremity.
as percentage.t car
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ization for their procedure, had higher rates of congestive
heart failure, cardiac arrhythmias, hypertension, hyperlipid-
emia, diabetes, renal disease, and cancer, and had Medicaid
insurance or were uninsured (Table I).
Perioperative stroke, mortality, stroke/death, and
cardiac complication rates in unmatched populations.
In the total cohort, the mortality, incidence of periopera-
tive stroke, and combined stroke/mortality were signifi-
cantly higher for CAS vs CEA: 1.2%, 3.7%, and 4.3% for
CAS, and 0.3%, 1.7%, and 1.9% for CEA, respectively
(Table II, A). The same was true in the asymptomatic
cohort, although the differences between the two proce-
dures in all of the above outcomes were numerically less
pronounced (0.8%, 2.6%, and 3.1% in CAS vs 0.3%, 1.5%,
and 1.7% in CEA group, respectively). In the symptomatic
cohort, the mortality rate was 8 times higher in women
undergoing CAS vs CEA (3.4% vs 0.4% in CEA), whereas
perioperative stroke and combined stroke/mortality rates
in CAS were at least 2.5 times higher than in CEA (9.4%
and 10.9% in CAS vs 3.5% and 3.8% in CEA, respectively).
There was no significant difference in the occurrence of
cardiac complication in the total and asymptomatic female
population undergoing CEA or CAS (Table II, A). How-
ever, the CAS procedure in symptomatic women was asso-
ciated withmore cardiac complications thanCEA (10.6% vs
6.5%; P  .0077). CAS was also associated with higher
incidence of perioperative hypotension in both symptom-
atic and asymptomatic groups (Table II, A).
Comparison of outcomes between propensity
score-matched cohorts. Three propensity-matched co-
Table II. In-hospital mortality and postoperative complic
artery stenting (CAS) for asymptomatic, symptomatic and
and (B) rates for cohorts matched by propensity score
A, Unmatched population
Variables
Asymptomatic
CEA, % CAS, %
P(n  16,576) (n  1943)
Stroke/mortality 1.71 3.09 .0001
Post-op stroke 1.54 2.62 .0004
Mortality 0.33 0.82 .0007
Cardiac complications 4.65 4.89 .6295
Postoperative hypotension 1.66 5.20 .0001
B, Matched population
Variables
Asymptomatic
CEA, % CAS, %
P(n  1801) (n  1801) (
Stroke/mortality 2.17 3.11 .0779
Post-op stroke 2.05 2.67 .2273
Mortality 0.39 0.78 .1266
Cardiac complications 4.28 4.89 .3769
Post-op hypotension 1.72 5.27 .0001horts of patients were created: total (2146 pairs of CAS and gEA patients), asymptomatic (1801 pairs), and symptom-
tic (287 pairs). In the total and symptomatic groups, CEA
ad lower incidence than CAS of stroke, mortality, and
omposite stroke/mortality (Table II, B). In asymptomatic
atients after matching, a trend toward worse outcomes
fter CAS did not reach statistical significance (Table II, B).
Outcomes after CAS and CEA in high-risk clinical
ubgroups. In high-risk clinical subgroups within asymp-
omatic and symptomatic cohorts, CEA also fared better
han CAS (Figs 1 and 2). The most pronounced differences
n perioperative stroke rates favoring CEA vs CAS were
een in clinical high-risk subgroups of symptomatic women
Fig 1, B), women with renal disease (5.3% vs 15.4%; P 
041), and octogenarians (5.7% vs 14.0%; P  .0056).
ifferences in combined stroke/mortality rates were also
ore pronounced in symptomatic women with renal dis-
ase (5.3% vs 17.9%; P  .0158) and in symptomatic
ctogenarians (6.1% vs 18.6%; P  .0001; Fig 2, B).
Multivariable regression analysis. After adjusting for
ymptoms found on admission, various comorbidities (see
ethods), age, race, insurance type, year of procedure, and
ospital annual volume, we found that CAS and Medicaid
nsurance status were the strongest predictors of postoper-
tive stroke, each increasing the odds for periprocedural
troke by twofold in the total cohort (Table III). In de-
cending order, CAS, cancer, symptoms on admission, and
edicaid insurance were among the strongest predictors of
he combined outcome of stroke/mortality (Table IV).
hen risk analysis was performed for the symptomatic and
symptomatic groups separately, in the asymptomatic
omen we identified (in descending order) Medicaid, con-
rates after carotid endarterectomy (CEA) and carotid
cohort of women: (A) observed rates before matching,
Symptomatic Total
, % CAS, %
P
CEA, % CAS, %
P1744) (n  350) (n  18,320) (n  2293)
78 10.86 .0001 1.91 4.27 .0001
50 9.43 .0001 1.72 3.66 .0001
40 3.43 .0001 0.33 1.22 .0001
54 10.57 .0077 4.83 5.76 .0521
78 4.29 .0035 1.67 5.06 .0001
Symptomatic Total
, % CAS, %
P
CEA, % CAS, %
P287) (n  287) (n  2146) (n  2146)
8 12.54 .0015 2.38 4.29 .0006
8 11.15 .0067 2.10 3.73 .0016
0 3.83 .0009 0.42 1.21 .0041
7 10.45 .0768 4.66 5.69 .1326
4 4.53 .0593 1.44 5.17 .0001ation
total
CEA
(n 
3.
3.
0.
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CEA
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death after carotid intervention. In the symptomatic group,
CAS, rheumatoid arthritis, cancer, and patient age were
associated with higher rates of stroke or death after the
procedure (Table IV).
Table V shows that CAS was a positive predictor of
death, stroke, and composite outcome of mortality/stroke
for symptomatic and asymptomatic women after adjusting
for all relevant baseline covariates (P  .2) in multivariable
logistic regression analysis. CAS increased the odds of
mortality eightfold and remained a very strong predictor
(threefold increase) for periprocedural stroke and compos-
ite outcome of stroke/mortality in symptomatic women.
CAS remained the risk factor of perioperative cardiac events
Fig 1. Postoperative in-hospital stroke rates for (A) asymp
tomy (CEA) or carotid artery stenting (CAS). CAD, Coro
Fig 2. Postoperative rates of combined outcome of st
women after carotid endarterectomy (CEA) or carotid
diabetes mellitus. *P  .05.after adjusting for relevant covariates. rISCUSSION
On the basis of the data from the American Vascular
ssociation screening program in 2002 to 2003, the prev-
lence of carotid stenosis 50% in elderly women (average
ge, 68 years) is 6% vs 8% in men,14 and it is likely to
ncrease in the older female population. The management
f carotid disease in women, both by medical therapy and
ntervention, historically has suffered from underdiagnosis
f disease, atypical symptomatology,15,16 and suboptimal
se of treatment. For instance, insufficient antiplatelet
reatment of cerebrovascular and cardiovascular disease14
nd poor enrollment of women in major antiplatelets trials
as been documented in the United States and Eu-
tic and (B) symptomatic women after carotid endarterec-
rtery disease; DM, diabetes mellitus. *P .05.
or death for (A) asymptomatic and (B) symptomatic
stenting (CAS). CAD, Coronary artery disease; DM,tomaroke
arteryope.17,18
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been scrutinized and validated by many historical trials. For
women, though, the role of CEA remains an open question
mostly due to low recruitment rate and inability to perform
meaningful sex subgroup analysis. The initial reports of the
North American Symptomatic Carotid Endarterectomy
Trial (NASCET) and the European Carotid Surgery Trial
(ECST), the two most frequently cited trials regarding the
use of CEA in symptomatic patients, omitted subgroup
analysis by sex2,3 because only one-third or fewer women
Table III. Risk factors for in-hospital perioperative
stroke based on the results of the multivariable
regressions analysis of the total cohort of womena
Variable OR (95% CL) P
CAS 2.29 (1.74, 3.01) .0072
CAS annual volume 0.99 (0.99, 0.998) .0001
Symptomatic 2.10 (1.61, 2.75) .0001
Age 1.02 (1.01, 1.03) .0017
Emergency procedure 1.49 (1.18, 1.88) .0009
Congestive heart failure 1.58 (1.15, 2.16) .0043
Pulmonary 1.29 (1.03, 1.61) .0262
Cancer 2.08 (1.08, 4.01) .0283
Medicaid 1.84 (1.13, 2.99) .0141
CAS, Carotid artery stenting; CL, confidence limits; OR, odds ratio.
aOnly significant parameters (P  .05) are included in the model.
Table IV. Risk factors for combined outcome of in-
hospital stroke/mortality based on the results of the
multivariable regression analysis
Variable OR (95% CL) P
Total cohort
CAS 2.39 (1.84, 3.09) .0001
CAS annual volume 0.99 (0.99, 0.998) .005
Symptomatic 1.95 (1.52, 2.51) .0001
Age 1.02 (1.01, 1.03) .0001
Black race 1.47 (1.02, 2.11) .0366
Emergency procedure 1.58 (1.27, 1.97) .0001
Congestive heart failure 1.71 (1.28, 2.28) .0003
Pulmonary 1.26 (1.01, 1.56) .0365
Renal 1.40 (1.03, 1.89) .0304
Cancer 2.05 (1.09, 3.84) .0257
Medicaid 1.78 (1.12, 2.84) .0156
Asymptomatic women
Medicaid 1.91 (1.13, 3.23) .0163
Congestive heart failure 1.90 (1.37, 2.62) .0001
Emergency procedure 1.78 (1.40, 2.27) .0001
CAS 1.68 (1.26, 2.24) .0004
Pulmonary 1.45 (1.15, 1.84) .0019
Renal 1.44 (1.02, 2.05) .0402
Age 1.02 (1.004, 1.03) .0102
CEA annual volume 1.00 (0.997, 1.00) .0158
Symptomatic women
CAS 3.31 (2.17, 5.04) .0001
Age 1.04 (1.02, 1.06) .0002
Rheumatoid arthritis 2.61 (1.19, 5.71) .0162
Cancer 2.65 (1.00, 7.03) .05
CAS, Carotid artery stenting;CEA, carotid endarterectomy;CL, confidence
limits; OR, odds ratio.were enrolled in these trials. dThe largest trials recommending the use of CEA in
symptomatic patients (the VA Cooperative trial, the
symptomatic Carotid Atherosclerosis Study [ACAS], and
he Asymptomatic Carotid Surgery Trial [ACST]) either
id not analyze women or did not find a significant differ-
nce for women. The VA Cooperative trial studied only
en. The ACAS reported a 66% (95% confidence interval
CI], 36%-82%) 5-year relative stroke risk reduction for
en and statistically insignificant reduction of 17% for
omen (95% CI, 96% to 65%).1 This discrepancy was
ttributed to the higher perioperative rate of composite
utcome of death or stroke seen in women compared with
en (3.6% vs 1.7%; P  .12). Finally, ACST claimed a
ong-term nonperioperative risk reduction of stroke for
omen of 4.1%; however, this benefit seemed at best very
arginal when compared with the perioperative stroke or
eath rate of 3.8%.5
The introduction of CAS has further complicated the
uestion of what is the best treatment of carotid disease in
omen. In theory, women should fare well with CAS or at
east experience equivalent outcomes with men. The ca-
otid arteries in women compared with men are higher-
elocity vessels,19 with increased outflow/inflow ratio,20
nd the carotid plaque, in general, has more stable charac-
eristics.21 All these parameters are usually associated with
uperior immediate and long-term outcomes after CAS.
On the other hand, women tend to have atherosclerotic
isease mainly distributed in the common carotid artery
ather than in the proximal internal carotid, which is usually
een in men.20 This may cause challenges when the lesions
re traversed during CAS. Indeed, many small retrospective
tudies showed equivalent outcomes between men and
omen after CAS.22-27 In one study,28 we reported our
xperience from 97 CAS procedures performed in 93
omen and 141 interventions in 135 men. There were no
ex-associated differences in stroke rate (2.1% in women
nd 4.2% in men; P  .48), death rate (0% vs 0.7%; P 
99), or cardiac events (3.2% vs 0.7%; P .3). It is certainly
fact that none of these studies had sufficient power to
rove statistical significance in small, as expected, differ-
nces in outcomes, or to evaluate outcomes separately in
symptomatic and symptomatic women.
The CREST trial,9,29 with a prespecified gender-re-
ated subgroup analysis, showed results that were similar to
urs regarding carotid intervention in women. Women
ndergoing CAS had higher perioperative stroke rates
5.5% vs 2.2% in CEA; P  .01) and no difference in
erioperative MI rates (1.5% in CAS vs 1.7% in CEA; P 
81). The CREST trial, even at its early phase,30 did show
ge80 years was a risk factor for increased adverse events
fter CAS. These results may have contributed to some
election bias seen in our study, where women undergoing
EA tend to be slightly older (72.0 vs 70.1 years; P 
0001) and had a higher proportion of octogenarians
23.5% vs 20.7%; P  .0033). However, unlike our study,
REST did not identify clinical subgroups of women who
ould benefit differently from CAS or CEA, nor did it
elineate risk factors associated with worse outcomes. To
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August 2012340 Vouyouka et alour knowledge, our study is the first that attempts to make
such comparative analyses of perioperative outcomes in
women undergoing CEA or CAS.
This study is the first to analyze large state hospital
discharge databases for periprocedural outcomes and risk
factors associated with carotid interventions in women and
suitability of CAS for the treatment of symptomatic carotid
stenosis in women. Our data suggested superior overall
immediate outcomes after CEA compared with CAS. The
overall in-hospital periprocedural combined stroke/mor-
tality rates after CEA were 1.7% in asymptomatic women
and 3.8% in symptomatic women, both of which are supe-
rior to the outcomes reported for women in meta-analysis
of large published trials. However, we observed significant
differences in the combined end point for the two different
treatment modalities, particular for symptomatic women.
Although the difference in this outcome in asymptomatic
women was 1.4%, in symptomatic women, the difference
was a dramatic 7.1%. Marginal procedurally related differ-
ences were also observed in high-risk subgroups of the
asymptomatic patients. However, in symptomatic women
and,more importantly, in symptomatic clinical subsets such
as octogenarians and women with renal failure or diabetes,
the rates of stroke or death reached levels (approximately
18%) that should be considered prohibitive.
Administrative data sets, such as the state discharge
data sets we used, do not have clinical details and therefore
we could not determine the clinical severity of the strokes
reported. Because a substantial number of the CAS proce-
dures were probably done as part of a study that required
meticulous postoperative neurologic evaluation of the pa-
tient by a neurologist, some neurologic events after CAS
might possibly have been over-reported. To deal with this,
we excluded codes for postprocedural transient ischemic
attacks. But, even this potential source of bias cannot
explain why the differences in stroke rates between CAS
and CEA remain rather small in asymptomatic women
compared with the differences seen in the symptomatic
group. Asymptomatic patients undergoing CAS are more
likely to be included in a clinical trial or a registry and
therefore are more likely to receive a postoperative neuro-
logic examination by a specialist compared with symptom-
atic patients undergoing CAS. Centers for Medicaid and
Table V. Carotid stenting procedure as a risk factor for va
symptomatic womena
Outcome
Total
OR (95% CL) P
Mortality 3.65 (2.20, 6.07) .0001
Post-op stroke 2.29 (1.74, 3.01) .0072
Stroke/mortality 2.39 (1.84, 3.09) .0001
Post-op cardiac complications 1.22 (0.99, 1.50) .0684
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CL, confidenc
aOutcomes after adjustment for baseline comorbidities, age, race, annual ho
performed (based on the results of multivariable logistic regression analysis)Medicare Services cover CAS in symptomatic high-risk catients and therefore their enrollment into a trial or a
egistry is not necessary to receive the procedure.
When it comes to cardiac events after carotid interven-
ions, similar to what was observed in CREST,9 we noted
o significant difference in cardiac complications in CEA
nd CAS cohorts when the whole female population was
nalyzed. Interestingly, cardiac events were more frequent
n symptomatic women who underwent CAS compared
ith those who underwent CEA (10.6% vs 6.5%; P 
008), and CAS remained a significant predictor of periop-
rative cardiac events, especially in symptomatic women,
ven after adjustment for all relative covariates (Table V).
he reasons for the above are not clear. Although CAS is a
ess invasive procedure compared with CEA and, therefore,
ess likely than CEA to require general anesthesia, CAS
ould conceivably be associated with an equal or higher
requency of cardiac events because it is more frequently
omplicated with periprocedural hypotension (5.2% vs
.7% in CEA for asymptomatic, and 4.3% vs 1.8% for
ymptomatic women), as shown in our study. Perioperative
ypotension could have triggered unwanted cardiac events.
econd, the risk adjustment of our multivariable model
ould be challenged by the inherent limitations of our
atabase where the severity of each comorbidity cannot be
ccurately assessed. These findings at least deserve further
ocused investigation with other large-scale or randomized
rials.
It is a notable finding that Medicaid insurance status
long with symptomatic status and CAS were strong pre-
ictors for perioperative stroke and composite adverse out-
omes. This finding concurs with other reports that show
he similar association of Medicaid insurance status with
orse outcomes during the management of other patho-
ogic entities such as coronary artery disease, cancer, and
heumatoid arthritis.31-34 Reasons are not quite under-
tood. In those reports, some of the reported reasons for
uch finding include low-volume centers undertaking the
are of Medicaid recipients and poor medical optimization.
nterestingly, Medicaid remained a poor predictor after
ntervention in our study even after we adjusted for annual
ospital volume in CEA and CAS. Our data indicate that
oor medical management and risk factor modification
ossibly may have played a major role in the inferior out-
outcomes in the total cohort and in asymptomatic and
Asymptomatic Symptomatic
OR (95% CL) P OR (95% CL) P
.38 (1.26, 4.49) .0079 8.01 (3.08, 20.84) .0001
.84 (1.31, 2.60) .0004 3.22 (1.93, 5.36) .0001
.90 (1.38, 2.62) .0001 3.49 (2.15, 5.66) .0001
.08 (0.85, 1.37) .5359 1.93 (1.23, 3.05) .0044
s; OR, odds ratio.
volume (CAS, CEA), type of admission, and year when the procedure was
nown parameters with P  .2 were included in the risk adjustment model.rious
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1
e limitomes observed in Medicaid patients.
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Volume 56, Number 2 Vouyouka et al 341Finally, it is also remarkable that most of the procedures
in New York and Florida in 2007 to 2009 were done for
asymptomatic disease and only 10.5% of the CEA and
16.7% of the CAS procedures were performed in symptom-
atic women. This proportion of symptomatic to asymptom-
atic patients is similar to other studies using the administra-
tive data sets11,35,36 and different from populations
recruited in randomized clinical trials. For example, only
46.6% of the recruited women were asymptomatic in the
CREST trial. The fact that the study analyses women only
and not men makes the observation that 90% of patients
were asymptomatic even more interesting if one considers
that some historical trials failed to prove a significant benefit
of carotid interventions in asymptomatic women. This
highlights the need for more sex-specific trials that will
provide solid information regarding the management of
carotid disease in women, define procedural indications for
different risk groups, and provide clear guidelines for the
community.
The administrative data sets to compare outcomes after
CEA and CAS procedures had been used by other authors
in the past. However, admittedly, selecting ICD-9-CM
codes to define the postoperative stroke is challenging. For
instance, McPhee et al35,37 defined postoperative stroke
with ICD-9-CM code 997.02 (iatrogenic postoperative
stroke) alone and demonstrated worse outcomes after CAS
compared with CEA in the general population using the
Nationwide Inpatient Sample (NIS) database. However,
many patients with postoperative neurologic events are
often not assigned this ICD-9-CM code,38 which is why we
used a combination of codes to define perioperative stroke,
including hemiplegia, intracerebral hemorrhage, cerebral
embolism with infarction, cerebral artery occlusion with
infarction, and aphasia that occurred during carotid inter-
vention hospitalization.11
Recently Rockman et al39 used NIS data to analyze
sex-related differences in outcomes after carotid interven-
tions. They did report postoperative stroke rates in asymp-
tomatic women undergoing CEA and CAS (0.9% vs 2.1%;
P  .001) that were similar to ours. In symptomatic
women, they noted a postoperative stroke rate of 3.4% after
CEA, which is similar to our observations (3.5%) and an
almost twofold higher stroke rate after CAS (6.2%). Be-
cause of the relatively small number of patients, this differ-
ence failed to reach statistical significance (P  .1). In our
experience, when large administrative databases are used
for outcome analysis, certain challenges are involved in
differentiating complications or outcomes from pre-
existing disease and comorbidities. Regarding this issue,
the New York and Florida data sets allow preoperative and
postoperative events to be differentiated with the POA flag
next to the diagnosis codes, whereas the NIS used by
Rockman et al and other national databases do not. Poor
identification of the preoperative symptomatic status may
explain why Rockman et al observed a significantly lower
proportion of symptomatic women undergoing carotid
interventions (5.3%) compared with our study (11.2%).Finally, this analysis could not address long-term out-
omes because information beyond hospital discharge is
ot available. Although late complications appear to occur
fter CEA and CAS, the frequency of late events appears
imilar with both procedures, suggesting comparisons
ased on hospital outcomes are valid.
ONCLUSIONS
Combined perioperative stroke/mortality rates were
0.9% after CAS vs 3.8% after CEA in symptomatic women.
utcome differences between the two procedures were
ven more pronounced in high-risk symptomatic clinical
ubsets. In multivariable analysis, CAS was identified as an
ndependent predictor of adverse events in symptomatic
omen, associated with threefold to fourfold more fre-
uent perioperative occurrence of death or stroke com-
ared with CEA.We do acknowledge that these differences
ay be somewhat overstated because this is not a con-
rolled randomized study and our database has its own
imitations that do not allow accurate estimation of the
everity of the comorbidities and postoperative neurologic
vents. However, until more testing is available, these
ndings should be seriously considered when a carotid
ntervention is contemplated for symptomatic women. In
symptomatic women, the differences between CEA and
AS were less pronounced, with CAS having a 3.1% rate of
erioperative death or stroke (vs 1.7% after CEA) and,
herefore, CAS may be an acceptable treatment option in
omen not suitable for CEA.
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Volume 56, Number 2 Vouyouka et al 342.e1Appendix I (online only). Definition of symptomatic sta
Classification of Diseases, 9th Revision, Clinical Modificatio
Procedures ICD-9-CM code
38.12- Carotid endarterectomy
00.63- Percutaneous insertion of carotid artery sten
Appendix II (online only). International Classification o
codes for comorbidities and complications
Clinical entity
Comorbidities (admitting diagnoses or primary
or secondary diagnoses with present on
admission flag was “YES”)
Cardiac 093.2, 394,
404.13, 4
426.1, 42
V433, V4
Pulmonary 416, 417.9,
503, 504,
Renal 403.01, 403
440.1, 58
V562, V5
Hypertension 401, 402, 40
Peripheral vascular disease 440.20, 440
443.0, 44
Obesity 278
Hyperlipidemia 272
Neurologic disorders 330, 331, 33
344.0, 34
437.0, 43
Diabetes 250
Neck radiology 147, 148, 14
Cancer (except of neck cancer) 140, 141, 14
158, 159,
181, 182,
197, 198,
Complications (primary or secondary diagnoses
with present on admission flag “NO”)
Postoperative stroke 997.02, 342
362.34, 3
Cardiac complications 410.00, 410
410.41, 4
410.90, 4
426.53, 4
428.23, 4
Hypotension 458.29tus for carotid artery disease based on International
n (ICD-9-CM) codes
Present (on admission) diagnoses (ICD9-CM code) for
symptomatic carotid artery disease
362.3-. Retinal vascular occlusion
362.84. Retinal ischemia
t(s) 433.11. Occlusion and stenosis of carotid artery with CI
433.31. Occlusion and stenosis of multiple and bilateral
arteries with CI
434.11. Cerebral embolism with CI
434.91. Cerebral artery occlusion, unspecified, with CI
435.8. Other specified transient cerebral ischemias
435.9. Unspecified transient cerebral ischemia:
impending cerebrovascular accident;
intermittent CI; transient ischemic attackf Diseases, 9th revision, Clinical Modification (ICD-9-CM)
ICD-9-CM code
395, 396, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.91,
04.93, 412, 413, 414.0, 424, 425.4, 425.5, 425.8, 425.9, 426.0,
6.7, 426.9, 427.0, 427.1, 427.2, 427.3, 427.9, 428, 429.2, V422,
50, V533
490, 491.0, 491.1, 492, 493.0, 493, 494, 495, 496, 500, 501, 502,
505, 506.0, 506.2, 506.4, 506.9, 508.1, 508.8, 508.9
.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93,
2, 583.0, 583.1, 583.2, 583.4, 585, 588.0, V420, V451, V561,
63, V568
3, 404, 405
.21, 440.22, 440.23, 440.24, 440.30, 440.31, 440.32, 440.8, 440.9,
3.1, 443.8, 443.9, 444.22, 447.1, V434
2, 333, 334.0, 334.1, 334.2, 334.4, 334.8, 335, 336, 342, 343,
4.1, 344.2, 344.3, 344.4, 344.5, 344.6, 344.9, 345, 348.1, 348.3,
7.3, 437.4, 437.5, 437.6, 437.7, 438.0, 438.1, 438.2, 438.3, 438.4
9, 161, 193, 230.0, 231.0, 231.1
2, 143, 144, 145, 146, 150, 151, 152, 153, 154, 155, 156, 157,
160, 162, 163, 164, 165, 170, 171, 172, 174, 175, 176, 179, 180,
183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 194, 195, 196,
199, 200, 201, 202, 203.0, 238.6
.90, 431, 434.11, 434.91, 784.3, 362.30, 362.31, 362.32, 362.33,
62.84, 997.01, 437.1, 436
.01, 410.10, 410.11, 410.20, 410.21, 410.30, 410.31, 410.40,
10.50, 410.51, 410.60, 410.61, 410.70, 410.71, 410.80, 410.81,
10.91, 411.0, 411.1, 411.81, 413.9, 424.1, 426.0, 426.12, 426.13,
27.1, 427.31, 427.32, 427.5, 427.5, 427.81, 427.89, 428.8, 428.31,
28.31, 428.33, 428.41, 428.43, 785.51, 996.61, 997.1
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August 2012342.e2 Vouyouka et alAppendix III (online only). Baseline characteristics of total, asymptomatic, and symptomatic cohorts of women who
underwent carotid intervention after matching by propensity score
Variablea
Total Asymptomatic Symptomatic
CEA CAS
P
CEA CAS
P
CEA CAS
P(n  2117) (n  2117) (n  1801) (n  1801) (n  287) (n  287)
Age, years 70.6  0.22 70.3  0.22 .2971 70.4  0.23 70.4  0.24 .89 70.0  0.71 70.0  0.75 .9244
Octogenarians 21.6 20.9 .5365 19.4 20.4 .4386 24.7 24.7 .99
Race
Native American 0.7 0.5 .5485 0.8 0.6 .4142 0.7 0.3 .5637
Asian 0.4 0.5 .4913 0.4 0.4 .99 0.7 1.0 .6547
Black 5.1 5.5 .5716 5.4 5.0 .5946 10.5 8.4 .4142
White 88.0 86.9 .2777 86.8 87.8 .3571 81.9 84.0 .5316
Other race 5.0 5.3 .6144 5.1 4.9 .8119 4.9 4.9 .99
Unknown race 0.9 1.3 .2382 1.5 1.3 .5637 1.4 1.4 .99
Emergency
hospitalization 31.9 30.5 .3173 24.5 24.3 .8709 72.1 69.3 .4283
Comorbid conditions
Symptomatic
presentation 16.2 14.2 .06 0.0 0.0 100.0 100.0
Cardiac 52.0 52.3 .821 53.9 53.1 .5952 53.3 50.9 .5555
Congestive heart
failure 9.7 9.6 .9156 9.6 9.4 .8632 9.8 10.5 .7855
Cardiac arrhythmia 12.3 11.7 .5321 11.2 11.2 .99 16.4 16.0 .9042
Valvular disease 7.9 7.3 .4158 7.8 7.0 .3359 7.3 8.0 .7576
Coronary disease 43.6 44.1 .6991 46.2 45.0 .4367 40.8 40.4 .9324
Pulmonary 20.4 20.2 .8781 21.4 20.1 .3231 18.8 19.5 .8312
COPD 1.6 1.9 .4061 1.6 1.8 .6056 2.1 2.1 .99
Other pulmonary
diseases 19.0 18.8 .843 19.9 18.8 .3744 16.7 17.4 .8231
Pulmonary
circulation 1.2 1.4 .6858 1.2 1.1 .6394 2.1 2.4 .7815
Hypertension 77.3 77.8 .6444 78.4 77.3 .4265 80.5 81.2 .833
Hyperlipidemia 59.2 57.3 .2041 60.5 57.7 .0834 55.4 56.4 .7991
Diabetes 31.2 31.0 .8915 30.3 31.1 .6018 39.0 33.1 .1434
Liver disease 0.7 0.7 .8527 0.8 0.7 .6949 0.3 0.3 1.0
PVD 23.4 22.9 .6845 23.7 23.0 .6293 23.3 23.0 .923
Significant LE
ischemia 0.8 0.7 .5775 0.8 0.6 .4142 0.7 0.7 .99
Renal
atherosclerosis 2.5 2.5 .9215 2.5 2.7 .7505 2.1 2.4 .7815
Other vascular
atherosclerosis 21.6 21.3 .7915 22.2 21.4 .5637 21.3 21.3 .99
Renal disease 8.0 8.5 .6121 8.9 8.3 .4669 11.1 10.1 .6858
Cancer 1.4 1.4 .8886 1.7 1.2 .2076 2.1 1.4 .5271
Neck cancer 1.3 1.4 .7855 1.2 1.2 .99 0.3 1.4 .1797
Other cancer 1.3 1.0 .2967 1.6 0.9 .0641 2.1 1.0 .3173
Rheumatoid
arthritis 2.8 2.6 .7055 2.9 2.6 .6002 2.4 2.8 .7815
Obesity 6.7 6.4 .656 5.1 5.9 .294 10.1 9.4 .7681
Insurance status
Medicare 72.2 71.5 .5914 72.1 73.1 .4822 63.8 65.5 .667
Medicaid 4.3 4.8 .4083 4.4 4.6 .8059 8.0 7.0 .6219
Commercial 19.8 20.1 .8099 20.5 19.3 .3666 22.6 22.3 .9237
Other insurance 1.7 1.9 .714 1.9 1.8 .8997 1.0 1.7 .4795
Uninsured 1.9 1.7 .5688 1.1 1.2 .8759 4.5 3.5 .5316
Annual hospital
volume
CAS 40.3  0.81 40.3  0.81 .9195 40.6  0.82 40.9  0.83 .7263 34.7  1.52 33.9  1.54 .58
CEA 114.9  1.71 111.1  1.39 .0545 116.5  1.69 112.5  1.84 .0646 111.4  3.89 107.0  4.83 .4715
Probability .284657 .284566 .1928 .27666 .276507 .1594 .329245 .329535 .6858CAS, Carotid artery stenting; CEA, carotid endarterectomy; COPD, chronic obstructive pulmonary disease; LE, lower extremity.
aContinuous data are presented as the mean  standard error and categoric data as percentage.
